Inovio Pharmaceuticals (INO) Down Almost 33% For the Week

Inovio Pharmaceuticals (INO) tumbled almost 33% over the past week. The investor sell-off is largely in part due to the Company’s shift in focus from a Covid-19 vaccine to a Covid-19 booster.

This also comes on the heels of their Q1’22 financial results and the appointment of a new CEO – Jacqueline Shea, Ph.D.

“We believe in the potential of our DNA medicines and vaccines to combat infectious diseases, cancer and HPV-associated diseases,” said Dr. Jacqueline Shea, President and CEO of INOVIO. “To achieve these goals, INOVIO must strategically prioritize our resources to capitalize on its demonstrated ability to generate functional T-cell and antibody immune responses, lack of anti-vector response, tolerability for re-administration and favorable temperature stability for transport, storage and distribution.”


INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit

Share This Article


About the Author

Inovio Pharmaceuticals (INO) Down Almost 33% For the Week

Editor Prism MarketView